Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

BB Biotech

SW: BION

Market CapCHF4559m

Last Close CHF82.3

BB Biotech (BION) is a Switzerland-based investment company, targeting long-term capital growth from biotechnology companies that are developing and marketing innovative drugs. At least 90% (currently 100%) of the portfolio is invested in listed companies, primarily those that already have products on the market or have promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotechnology index (in Swiss francs) but is managed on a bottom-up basis, with a concentrated c 20–35 stock portfolio.

More BB Biotech content >

Investment summary

BB Biotech (BION) provided a solid platform of growth for its investors in FY20, with Swiss franc share price and NAV total returns of 19.3% and 24.3% respectively, outperforming the Nasdaq Biotechnology index in NAV terms amid a weaker environment for the US dollar. While the fund’s investment in mRNA platform company Moderna (share price +509% over 12 months) was the standout story after the rapid development of its successful COVID-19 vaccine, the BION team has been focused on backing companies bringing new technologies to bear in a number of innovative areas. This included investments at IPO in companies such as Generation Bio and Relay Therapeutics. BION has declared a cash distribution of 5% (CHF3.60) for FY20, which equates to a current yield of 4.3%.

Content on BB Biotech
BB Biotech – Looking for innovation beyond the pandemic
Investment companies | Review | 1 March 2021
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
BB Biotech – fund manager interview
Investment companies | Edison TV | 15 December 2020
BB Biotech – RNA focus provides a possible COVID-19 solution
Investment companies | Review | 16 April 2020
Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.
View more
Register to receive research on BB Biotech as it is published
Sector
Investment companies
Access more Investment companies content
Share price graph
Price performance
%
1m
3m
12m
Actual (6.3) (4.7) 29.0
Relative* (8.2) (5.2) 9.0
52-week high/low CHF92.2/CHF58.1
*% relative to local index
Key management
Erich Hunziker Chairman
Claude Mikkelsen Director of IR
Daniel Koller Head of investment management
Dr Silvia Siegfried-Schanz Director, investor relations